AVX-1

AVX-1 asks whether the α2A-adrenergic autoreceptor’s response to endogenous norepinephrine can be strengthened in a way that reinforces autoinhibitory feedback and remains dependent on the endogenous signal.

α2A-adrenergic autoreceptor
Planned drug format: small molecule (chemically synthesized compound)
Noradrenergic dysregulation
Computational design · Patent pending
Updated August 21, 2026

Current stage

AVX-1 is in computational design. The current stage connects the program’s physiological question to molecular designs and the experiments required to evaluate them. Synthesis and experimental pharmacology are the next material validation stages. The intended mechanism and signalling profile remain program objectives.

Research objective

α2A autoreceptors participate in the feedback system that regulates norepinephrine release. AVX-1 is designed to investigate a state-dependent intervention at that control point.

Published preclinical evidence indicates that α2A autoreceptors participate in presynaptic inhibitory control of norepinephrine release. Aeviant uses that regulatory role to define the program objective: positive allosteric modulation whose activity depends on the endogenous signal.

Aeviant classifies that interpretation as the program hypothesis. Experimental evidence is required to evaluate it. The literature and its limitations are reviewed on the α2A autoregulation page.

What the program must show

The core requirements are reproducible potentiation in the presence of endogenous norepinephrine, acceptably low intrinsic agonism, receptor-subtype selectivity and the intended Gi-biased, arrestin-sparing signalling profile.

Further work would need to establish tractable chemistry, coherent results across independent methods, appropriate tissue exposure and an acceptable cardiovascular, autonomic and overall safety profile.

AVX-1 advances only if those results support the intended pharmacology and justify the next stage. The program will be redirected or stopped if direct agonism dominates, ligand dependence or subtype selectivity fails, functional evidence contradicts the model, or the required exposure and therapeutic window are impractical.

Development path

The initial literature framework and computational target characterization are complete. Aeviant has filed a patent application relating to aspects of the program.

The current campaign generates molecular designs, challenges them against the required state-dependent behaviour and prioritizes candidates and experiments for the next stage.

Chemistry, synthesis and experimental pharmacology form the next material decision point. Subsequent development would require evidence for exposure, safety, efficacy and translational relevance. Technical discussion beyond the public thesis requires a signed non-disclosure agreement.